The SURPASS ET Study which will be opening soon at Princess Margaret. This is a phase 3 randomized study of P1101 (ropeginterferon alfa-2b) vs. anagrelide for second line treatment of essential thrombocythemia. Key inclusion criteria are: - High-risk ET ( >60 years and/or prior thrombosis/hemorrhage) - Resistance/intolerance to hydroxyurea - Platelets > 450, WBC > 10 - Patients can have received prior interferon or anagrelide, as long as they do not have resistance, intolerance or other current contraindications Please speak to your hematologist or oncologist if you think you may be eligible.
top of page
bottom of page
コメント